前沿速览007期| CAR-T治B淋 前沿览新知
01
儿童癌症CAR-T细胞产品：为什么需要替代的开发路径
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed
第一作者：Rossig C
J Clin Oncol. 2023 Nov 27:JCO2301314.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37946255/
02
靶向CD19和CD20的T细胞重定向疗法治疗淋巴瘤后的序贯性抗原丢失和分支进化
Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy
第一作者：Duell J
Blood. 2023 Nov 17:blood.2023021672.
全文网址：https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27155
03
CD19 CAR T细胞输注后，CAR(+)和CAR(-) T细胞在B细胞恶性肿瘤患者中共享分化为NK样亚群的轨迹
CAR(+) and CAR(-) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
第一作者：Louie RHY
Nat Commun. 2023 Nov 27;14(1):7767.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1535-6108(23)00316-1
04
CAR-T细胞疗法的产品属性与二线大B细胞淋巴瘤（ZUMA-7）的疗效和毒性不同相关
Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)
第一作者：Filosto S
Blood Cancer Discov. 2023 Nov 20.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.27056
05
CD79b CAR-T细胞治疗B细胞淋巴瘤
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
第一作者：Chu F
J Immunother Cancer. 2023 Nov 24;11(11):e007515.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620596/
06
人源化框架优化了抗CD72纳米体CAR-T细胞治疗B细胞恶性肿瘤的效力
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
第一作者：Temple WC
J Immunother Cancer. 2023 Nov 24;11(11):e006985.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620597/
07
延迟输注CAR-T细胞对CAR-T治疗大B细胞淋巴瘤患者的疗效影响
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
第一作者：Jallouk AP
Haematologica. 2023 Nov 30.
全文网址：https://ashpublications.org/bloodadvances/article/7/21/6710/497690/Inflammatory-reactions-mimic-residual-or-recurrent
08
ARID1A和TP53突变对CAR-T细胞治疗儿童难治性或复发性成熟B细胞淋巴瘤的影响
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
第一作者：Li Y
Cancer Cell Int. 2023 Nov 19;23(1):281.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023009961/496695/A-phase-2-trial-of-defibrotide-for-the-prevention
09
基于人群的EASIX评分外部验证可预测CAR-T细胞相关毒性
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
第一作者：de Boer JW
Cancers (Basel). 2023 Nov 16;15(22):5443.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011470/498655/Transient-responses-and-significant-toxicities-of
10
CD19 靶向治疗对接受CD19 CAR-T细胞治疗后复发或难治的大B 细胞淋巴瘤患者的疗效
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
第一作者：Iqbal M
Bone Marrow Transplant. 2023 Nov 16.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/adma.202304122
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2023.11-17 valid until 2025.11
供稿与审核：临床开发与医学部